Angioedema treatment is mainly used to treat hereditary angioedema which is a rare genetic disorder characterized by recurrent episodes of swelling that may affect the hands, feet, limbs, face, intestinal tract, genitals or throat. Angioedema treatments are available in the form of drugs such as C1 esterase inhibitors, bradykinin B2 receptor antagonists, and selective Bradykinin B2 receptor antagonists. These drugs help inhibit the swelling caused by bradykinin, a protein that plays a key role in the swelling associated with angioedema. The global angioedema treatment market is estimated to be valued at US$ 470.4 Mn in 2023 and is expected to exhibit a CAGR of 4.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
The global angioedema treatment market is driven by increasing prevalence of hereditary angioedema globally. According to an article published by the U.S. National Library of Medicine in 2017, the prevalence of hereditary angioedema is approximately 1 per 50,000 individuals. Hereditary angioedema affects both genders equally and symptoms often begin in early adulthood. The genetic and molecular basis of hereditary angioedema has now been elucidated for almost all patients and gene mutations have been identified that lead to deficient levels or function of C1 inhibitor protein. With a lack of effective treatment options currently available for hereditary angioedema patients, there is a need for safe and reliable on-demand and prophylactic treatments for the condition to help treat swelling. This represents a prominent opportunity for various pharmaceutical companies developing novel drugs for angioedema treatment.
Increasing prevalence of hereditary angioedema is expected to drive growth of the global angioedema treatment market over the forecast period. According to an article published in the U.S. National Library of Medicine in 2017, the prevalence of hereditary angioedema is approximately 1 per 50,000 individuals. With a lack of effective treatment options currently available for hereditary angioedema patients, there is a need for safe and reliable on-demand and prophylactic treatments for the condition to help treat swelling. This represents a prominent driver for the market. Furthermore, recent drug approvals are also expected to support the market growth.
The global angioedema treatment market is dominated by the C1 esterase inhibitor segment. C1 esterase inhibitors are the first-line therapy for treating hereditary angioedema (HAE) attacks. These treatment options reduce the occurrence and severity of HAE attacks by preventing or inhibiting the production of bradykinin, the mediator substance that causes HAE symptoms. Their effectiveness in treating HAE attacks has increased their adoption rate over other treatment types.
Political: Governments across countries are focused on increasing access to essential medications for rare diseases like HAE through incentives for pharmaceutical companies and reimbursement programs. This is positively impacting the market growth.
Economic: Rising healthcare expenditures on advanced therapeutics for rare disorders and growing personal incomes are supporting increased patient affordability for high-cost treatment options in this market.
Social: Improving disease awareness initiatives by patient advocacy groups have increased diagnosis rates globally. This is expanding the potential patient population and market opportunities.
Technological: Biotechnology advances are resulting in the development of long-acting C1 esterase inhibitor replacements and oral treatment options. These novel therapies enhance patient adherence and convenience.
The global angioedema treatment market is expected to witness high growth over the forecast period supported by increasing disease diagnosis rates globally and launch of newer treatment alternatives. The North American region currently dominates the market due to established healthcare systems and growing patient access to premium therapeutics through reimbursement support. Key regional markets include the U.S., Germany, France, Italy, Spain, the U.K., China, Japan, India, and Brazil.
Key players operating in the angioedema treatment market are Bayer AG, Zoetis Inc., Boehringer Ingelheim GmbH, Merck & Co., Inc., Virbac S.A., Ceva Santé Animale, Elanco Animal Health, Bimeda, Aurobindo Pharma Limited, and Teva Pharmaceutical Industries Ltd. Bayer AG leads with its branded drug Berinert used for treating acute HAE attacks. Players are focusing on expanding their drug portfolios organically through R&D as well as inorganically through collaborations and M&A deals.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it